Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

Video

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Mark Fleury, PhD, principal of policy development, American Cancer Society Cancer Action Network, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

The COVID-19 pandemic presented a significant need to rapidly advance the utility of decentralized clinical trials, says Fleury. Historically, the oncology field anticipated that decentralized clinical trials would be an important aspect of offering patients more accessible and convenient clinical trial options away from the conventional clinical trial setting, Fleury explains.

It is important that the lessons learned from the pandemic, as well as the use of tools developed for decentralized clinical trials, continue even beyond the COVID-19 pandemic, concludes Fleury.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Related Content
Paul G. Kluetz, MD

Decentralization Efforts Could Engage Community Oncologists

May 9th 2023
Article
Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

June 6th 2022
Podcast
Electra D. Paskett, PhD

Delays in Cancer Screenings Due to COVID-19 May Result in Trend Toward Excess Deaths

March 24th 2023
Article
Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients

June 2nd 2022
Podcast
Maurie Markman, MD

Time Required to Address Scientific Questions Generates an Information Dilemma

October 26th 2022
Article
Mili Arora, MD

In the Trenches With the Fellows

July 8th 2022
Article